Event Date/Time: Apr 25, 2012 | End Date/Time: Apr 26, 2012 |
Description
Diabetic retinopathy is the leading cause of blindness in working age people2. It affects 80% of patients who have had diabetes for 10 years or longer and results in a huge financial burden3. This conference will look at the latest advances in this field and the results of key clinical trials.
Visiongain's 6th Annual Diabetes Conference will provide a unique networking event to boost your understanding of:
- Combating microvascular damage caused by hyperglycaemia using new drugs and management techniques
- Targeting the build up of cholesterol and lipid in the arteries which are exacerbated in diabetes due to dislipidaemia
- Challenges for development of new drugs such as study design, clinical trial regulations and approval of drugs
- Market trends for the future of the diabetic market, including looking at disease epidemiology and methods to penetrate developing markets
- Development of monocolonal antibody treatments to target proliferative retinopathy
- Advances in next generation glucose monitoring equipment that is less invasive to help increase patient compliance with regular testing
- The implications of inflammation in the body as a result of diabetes and its effects on vascular disease
- Using GLP-1 analogues to treat obesity and diabetes
- Regulatory updates in diabetic care from the MHRA
- Results of key clinical trials (EUCLID, RASS, ASPEN, FIELD)